Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price reached a new 52-week low on Wednesday . The stock traded as low as $184.08 and last traded at $184.08, with a volume of 11 shares. The stock had previously closed at $191.13.
Genmab A/S Stock Down 2.6 %
The company's fifty day moving average price is $205.72 and its 200 day moving average price is $214.87. The company has a market capitalization of $11.98 billion, a P/E ratio of 10.35 and a beta of 1.10.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
